{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:19:36Z","timestamp":1707524376834},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,6]]},"DOI":"10.7759\/cureus.17779","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T22:34:27Z","timestamp":1630967667000},"source":"Crossref","is-referenced-by-count":0,"title":["Cutaneous Multiple Myeloma"],"prefix":"10.7759","author":[{"given":"Leela Krishna Vamsee","family":"Miriyala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepti","family":"Avasthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel RL","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021, 71:7-33. 10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"SEER Cancer Statistics Review (CSR) 1975-2018. (2021). Accessed. April 15, 2021: https:\/\/seer.cancer.gov\/csr\/1975_2018\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.080","article-title":"Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma","volume":"10","author":"Talamo G","year":"2010","unstructured":"Talamo G, Farooq U, Zangari M, Liao J, Dolloff NG, Loughran TP Jr, Epner E. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2010, 10:464-8. 10.3816\/CLML.2010.n.080","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.054","article-title":"Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: a case series from Korea","volume":"78","author":"Woo YR","year":"2018","unstructured":"Woo YR, Kim JS, Lim JH, et al.. Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: a case series from Korea. J Am Acad Dermatol. 2018, 78:471-8.e4. 10.1016\/j.jaad.2017.08.054","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.028","article-title":"Cutaneous involvement in multiple myeloma (MM): a case series with clinicopathologic correlation","volume":"74","author":"Malysz J","year":"2016","unstructured":"Malysz J, Talamo G, Zhu J, et al.. Cutaneous involvement in multiple myeloma (MM): a case series with clinicopathologic correlation. J Am Acad Dermatol. 2016, 74:878-84. 10.1016\/j.jaad.2015.12.028","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.012","article-title":"Cutaneous involvement in multiple myeloma mimicking acral-lentiginous melanoma","volume":"62","author":"Martorell A","year":"2010","unstructured":"Martorell A, Millan-Parrilla F, Gimeno-Carpio E. Cutaneous involvement in multiple myeloma mimicking acral-lentiginous melanoma. J Am Acad Dermatol. 2010, 62:1076-8. 10.1016\/j.jaad.2009.07.012","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.5070\/D32010024252","article-title":"Cutaneous involvement in multiple myeloma: a case report with an unusual location","volume":"20","author":"Youssef M","year":"2014","unstructured":"Youssef M, Letaief A, Elhani I, et al.. Cutaneous involvement in multiple myeloma: a case report with an unusual location. Dermatol Online J. 2014, 20:13030\/qt9s83h487.","journal-title":"Dermatol Online J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa122","article-title":"Cutaneous involvement in plasma cell myeloma","volume":"155","author":"Panse G","year":"2021","unstructured":"Panse G, Subtil A, McNiff JM, et al.. Cutaneous involvement in plasma cell myeloma. Am J Clin Pathol. 2021, 155:106-16. 10.1093\/ajcp\/aqaa122","journal-title":"Am J Clin Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2012.01547.x","article-title":"Cutaneous involvement in multiple myeloma: report of two cases","volume":"39","author":"Messeguer F","year":"2012","unstructured":"Messeguer F, Llombart B, Sanmart\u00edn O, Agusti-Mejias A, Traves V, Guill\u00e9n C. Cutaneous involvement in multiple myeloma: report of two cases. J Dermatol. 2012, 39:806-8. 10.1111\/j.1346-8138.2012.01547.x","journal-title":"J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1128542","article-title":"Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients","volume":"57","author":"Jurczyszyn A","year":"2016","unstructured":"Jurczyszyn A, Olszewska-Szopa M, Hungria V, et al.. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016, 57:2071-6. 10.3109\/10428194.2015.1128542","journal-title":"Leuk Lymphoma"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.4.475","article-title":"Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases","volume":"139","author":"Requena L","year":"2003","unstructured":"Requena L, Kutzner H, Palmedo G, et al.. Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases. Arch Dermatol. 2003, 139:475-86. 10.1001\/archderm.139.4.475","journal-title":"Arch Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2104-1","article-title":"Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?","volume":"105","author":"Marchica V","year":"2017","unstructured":"Marchica V, Accardi F, Storti P, et al.. Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?. Int J Hematol. 2017, 105:104-8. 10.1007\/s12185-016-2104-1","journal-title":"Int J Hematol"},{"key":"ref13","article-title":"New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000","author":"Curtis RE","year":"2006","unstructured":"Curtis RE, Freedman DM, Ron E, et al.. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute, Bethesda, MD; 2006."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody S","year":"2011","unstructured":"Mailankody S, Pfeiffer RM, Kristinsson SY, et al.. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood. 2011, 118:4086-92. 10.1182\/blood-2011-05-355743","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1998","article-title":"Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms","volume":"85","author":"Dong C","year":"2001","unstructured":"Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer. 2001, 85:997-1005. 10.1054\/bjoc.2001.1998","journal-title":"Br J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.014","article-title":"Risk of melanoma in patients with multiple myeloma: a Surveillance, Epidemiology, and End Results population-based study","volume":"78","author":"Chang TW","year":"2018","unstructured":"Chang TW, Weaver AL, Brewer JD, Kyle RA, Baum CL. Risk of melanoma in patients with multiple myeloma: a Surveillance, Epidemiology, and End Results population-based study. J Am Acad Dermatol. 2018, 78:621-3. 10.1016\/j.jaad.2017.10.014","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar SK","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, et al.. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008, 111:2516-20. 10.1182\/blood-2007-10-116129","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar SK","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, et al.. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014, 28:1122-8. 10.1038\/leu.2013.313","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data","volume":"16","author":"Pulte D","year":"2011","unstructured":"Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist. 2011, 16:1600-3. 10.1634\/theoncologist.2011-0229","journal-title":"Oncologist"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.05.012","article-title":"Role of thalidomide in the treatment of patients with multiple myeloma","volume":"88 Suppl 1","author":"Morgan GJ","year":"2013","unstructured":"Morgan GJ, Davies FE. Role of thalidomide in the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol. 2013, 88 Suppl 1:S14-22. 10.1016\/j.critrevonc.2013.05.012","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.760736","article-title":"Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma","volume":"54","author":"Brioli A","year":"2013","unstructured":"Brioli A, Kaiser MF, Pawlyn C, et al.. Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. Leuk Lymphoma. 2013, 54:1975-81. 10.3109\/10428194.2012.760736","journal-title":"Leuk Lymphoma"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal M","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, et al.. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012, 366:1782-91. 10.1056\/NEJMoa1114138","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo A","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, et al.. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012, 366:1759-69. 10.1056\/NEJMoa1112704","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy PL","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, et al.. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012, 366:1770-81. 10.1056\/NEJMoa1114083","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.114","article-title":"Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial","volume":"6","author":"Jones JR","year":"2016","unstructured":"Jones JR, Cairns DA, Gregory WM, et al.. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016, 6:e506. 10.1038\/bcj.2016.114","journal-title":"Blood Cancer J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/65532-cutaneous-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:28:35Z","timestamp":1707506915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/65532-cutaneous-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.17779","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,6]]}}}